4//SEC Filing
Nolan Sean P. 4
Accession 0001209191-23-001020
CIK 0001806310other
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:51 PM ET
Size
5.6 KB
Accession
0001209191-23-001020
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2022-12-30+1,106,131→ 1,106,131 totalExercise: $2.26Exp: 2032-12-30→ Common Stock (1,106,131 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option shall vest and become exercisable on December 16, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001569926
Filing Metadata
- Form type
- 4
- Filed
- Jan 3, 7:00 PM ET
- Accepted
- Jan 4, 4:51 PM ET
- Size
- 5.6 KB